
ImpleMMent
Bringing Bispecific Antibody Therapy Safely into Community Practice
A pilot educational initiative to support safe and effective delivery of bispecific antibodies in community oncology settings
About These Virtual In-Service Programs
Bispecific antibodies (BsAbs) are changing treatment for patients with relapsed/refractory multiple myeloma (RRMM). However, delivering them in a community practice can bring its own challenges. For example, step-up dosing and monitoring require resources; escalation protocols and managing side effects (e.g., cytokine release syndrome (CRS), ICANS, infections, and cytopenias) require clear processes; and optimal care requires coordination across potentially scattered care teams. But all of these things have to happen to implement these therapies safely and effectively.
ImpleMMent is a CME-accredited virtual in-service built around your practice. Over 1.5 hours, a physician, an advanced practice nurse, and an oncology pharmacist walk your team through how to start or strengthen BsAb delivery in your clinic, using your workflows, your staffing, and your challenges.
There is no fee to host a session, and your team earns valuable CE credit at no cost. We take care of the heavy lifting. Only six practices will be selected for this pilot.
Your Session Is Built for Your Practice
Every ImpleMMent session uses the following process to ensure the education fits your clinic:
- Pre-planning call. We meet with your practice by Zoom to identify your site-specific pain points.
- Custom agenda. Faculty build the session specifically around this feedback.
- Virtual in-service. A 1.5-hour accredited session combines focused didactic content and open Q&A with the faculty to allow troubleshooting and access to expert insights.
- Implementation resources. Your team receives practical tools, such as step-up dosing protocols, monitoring templates, and patient education materials, to put what they learned into practice.
- Ongoing support. Faculty and the EfficientCME team remain available after the session for follow-up questions.
- Two-month check-in. Participating practices complete a brief follow-up survey and Zoom call to review progress and next steps.
What Your Team Will Address
- Choosing the right patients for BsAb therapy and sequencing treatment
- Recognizing and managing CRS, ICANS, infections, and cytopenias
- Running step-up dosing and monitoring with the staff and resources you have
- Defining roles, handoffs, and safety and escalation protocols across the team
- Educating patients, setting expectations, and obtaining informed consent
- Navigating REMS requirements, insurance authorization, and patient access
Facilities and Teams Who Should Participate
Community oncology teams that treat patients with MM, including physicians, advanced practice providers, nurses, and pharmacists. Each practice designates a hematologist-oncologist as its lead. These sessions are appropriate not only for practices just starting to offer BsAbs, but also for practices that want to improve how they already deliver them.
Host a Session at Your Facility
There is no fee to host a virtual in-service session, and complimentary meeting materials are provided. We take care of the heavy lifting—at no cost to your facility!
Programs are thoughtfully designed to address the unique needs of your interprofessional team and provide valuable CE credit at no cost to you. Interested in hosting a virtual session? Complete the form below or contact us at grandrounds@knowfully.com.
Virtual In-Service Program Description
Bispecific antibodies (BsAbs) are transforming treatment for patients with relapsed/refractory multiple myeloma (RRMM), yet their rapid integration into practice has created important knowledge, competence, and performance gaps, particularly in community oncology settings. Community clinicians may have limited experience selecting appropriate patients, sequencing these therapies, and anticipating and managing unique toxicities such as cytokine release syndrome, ICANS, infections, and cytopenias. Recent needs-assessment and outcomes data indicate that these gaps have persisted over time.
Beyond clinical knowledge, community practices face significant operational barriers to BsAb delivery, including staffing and infrastructure limitations, step-up dosing and monitoring requirements, interdisciplinary coordination, patient access, and development of appropriate safety and escalation protocols. This educational initiative will provide community-based oncology teams with practical, site-specific strategies and implementation resources to improve patient selection, toxicity management, and the safe, sustainable integration of BsAb therapy into routine RRMM care.
Target Audience
Medical oncologists, hematologists/oncologists, hem-onc fellows, oncology nurses, pharmacists, nurse practitioners (NPs), physician associates (PAs), and other health care professionals who treat patients with RRMM
Learning Objectives
At the conclusion of this activity, learners will be able to better:
- Apply eligibility criteria and clinical decision pathways to identify and select patients with relapsed/refractory MM (RRMM) who may benefit from BsAb therapy
- Implement evidence-based strategies to anticipate, mitigate, and manage AEs associated with BsAb therapy, supporting safe and sustained treatment in diverse care settings
- Demonstrate practical approaches to operationalizing BsAb administration (e.g., coordination, monitoring, and patient access workflows) to overcome logistical challenges unique to community oncology practice
Book a Virtual In-Service Session Today!
Faculty From Mt. Sinai Medical Center, NY, NY

Joshua Richter
MD, FACP (Chair)
Associate Professor of Medicine
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
Director of Myeloma, Blavatnik Family Chelsea Medical Center at Mount Sinai
New York, NY

Donna D. Catamero
ANP-BC, OCN, CCRC
Associate Director, Myeloma Research
Program Director for Liquid Tumor Research Nursing
Adjunct Faculty, Mount Sinai Phillips School of Nursing
The Mount Sinai Health System
New York, NY

Marcus S Flores
PharmD, BCPS, BCOP
Outpatient Multiple Myeloma Pharmacotherapy Specialist
The Mount Sinai Hospital
New York, NY
Accreditation
Jointly Accredited Provider
In support of improving patient care, this activity has been planned and implemented by CME Outfitters, LLC, and Efficient CME. CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
IPCE
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education Credit for learning and change.
Physicians (ACCME)
CME Outfitters, LLC, for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses (ANCC)
This activity is designated for 1.5 contact hours.
Physician Assistants (AAPA)
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Pharmacists (ACPE)
This application-based activity is approved for 1.5 contact hours (0.15 CEUs) of continuing pharmacy credit (JA0007185-9999-26-134-L01-P).
Royal College MOC
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Certificate of Participation
This activity was certified for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education Credit for learning and change.
ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For more information, contact Kayla Ibarra at ibarrak@cmeoutfitters.com
Supported by educational grants from Johnson & Johnson and Regeneron.
